BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 14657217)

  • 1. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide.
    Schmieg J; Yang G; Franck RW; Tsuji M
    J Exp Med; 2003 Dec; 198(11):1631-41. PubMed ID: 14657217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.
    Yoshiga Y; Goto D; Segawa S; Horikoshi M; Hayashi T; Matsumoto I; Ito S; Taniguchi M; Sumida T
    Clin Exp Immunol; 2011 May; 164(2):236-47. PubMed ID: 21391989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.
    Smyth MJ; Crowe NY; Pellicci DG; Kyparissoudis K; Kelly JM; Takeda K; Yagita H; Godfrey DI
    Blood; 2002 Feb; 99(4):1259-66. PubMed ID: 11830474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
    Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
    J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner.
    Coppieters K; Van Beneden K; Jacques P; Dewint P; Vervloet A; Vander Cruyssen B; Van Calenbergh S; Chen G; Franck RW; Verbruggen G; Deforce D; Matthys P; Tsuji M; Rottiers P; Elewaut D
    J Immunol; 2007 Aug; 179(4):2300-9. PubMed ID: 17675491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
    Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
    Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
    Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-18 time-dependently modulates Th1/Th2 cytokine production by ligand-activated NKT cells.
    Uchida T; Kinoshita M; Fukasawa M; Habu Y; Shinomiya N; Seki S
    Eur J Immunol; 2007 Apr; 37(4):966-77. PubMed ID: 17330820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
    Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
    J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
    Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
    J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotoxin-induced lung injury in α-galactosylceramide-sensitized mice is caused by failure of interleukin-4 production in lung natural killer T cells.
    Dagvadorj J; Tumurkhuu G; Naiki Y; Noman AS; Iftakhar-E-Khuda I; Badamtseren B; Komatsu T; Koide N; Yoshida T; Yokochi T
    Clin Exp Immunol; 2010 Oct; 162(1):169-77. PubMed ID: 20659123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
    Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
    Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.
    Burdin N; Brossay L; Kronenberg M
    Eur J Immunol; 1999 Jun; 29(6):2014-25. PubMed ID: 10382765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.
    Gonzalez-Aseguinolaza G; de Oliveira C; Tomaska M; Hong S; Bruna-Romero O; Nakayama T; Taniguchi M; Bendelac A; Van Kaer L; Koezuka Y; Tsuji M
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8461-6. PubMed ID: 10900007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
    Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
    J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.